getLeronlimab.com
Business Services · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1111 Main St Ste 660, Vancouver, Washing...Phone Number
(360) 980-8524Website
www.getleronlimab.comRevenue
<$5 MillionIndustry
About getLeronlimab.com
CytoDyn is a biotechnology company focused on developing Leronlimab, a monoclonal antibody therapeutic drug aimed at treating metastatic triple-negative breast cancer (mTNBC) and HIV. The company is currently conducting clinical trials in the United States and Brazil to evaluate the drug's efficacy in treating severe COVID-19 symptoms. Intended clients include patients suffering from mTNBC, HIV, and critically ill COVID-19 patients, as well as healthcare providers seeking innovative treatment options. CytoDyn aims to address unmet medical needs with its promising therapeutic solutions.Explore more
SIC Code 87,873NAICS Code 54,541Show more
getLeronlimab.com Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to getLeronlimab.com
Compare insights from companies similar to getLeronlimab.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
getLeronlimab.com Tech Stack
A closer look at the technologies used by getLeronlimab.com
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding getLeronlimab.com
Sign Up For FreeTo access detailed company insights
CytoDyn is a biotechnology company focused on developing Leronlimab, a monoclonal antibody therapeutic drug aimed at treating metastatic triple-negative breast cancer (mTNBC) and HIV. The company is currently conducting clinical trials in the United States and Brazil to evaluate the drug's efficacy in treating severe COVID-19 symptoms. Intended cli... Read More
